Activation of ErbB2 and Downstream Signalling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Akhtar, Saghir ^a   Yousif, Mariam H M ^a   Dhaunsi, Gursev S ^a   Sarkhouh, Fatma ^a   Chandrasekhar, Bindu ^a   Attur, Sreeja ^a   Benter, Ibrahim F ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; CARBACHOL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; NORADRENALIN; RHO KINASE; SMALL INTERFERING RNA; STREPTOZOCIN; TYROSINE; ERBB2 PROTEIN, RAT; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EX VIVO STUDY; EXPERIMENTAL MODEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MESENTERY BLOOD FLOW; NONHUMAN; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STREPTOZOCIN DIABETES; UPREGULATION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; ANIMAL; CELL CULTURE; COMPLICATION; DIABETIC ANGIOPATHIES; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; MAPK SIGNALING; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION; WISTAR RAT;

RATTUS;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; MALE; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, WISTAR; RECEPTOR, ERBB-2; RHO-ASSOCIATED KINASES; TRANSCRIPTIONAL ACTIVATION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 84879533293     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067813     Document Type: Article

References (50)

1. Scully T, (2012) Diabetes in numbers. Nature 485: S2-S3.
2. Whiting DR, Guariguata L, Weil C, Shaw J, (2011) IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Research and Clinical Practice 94: 311-321.
3. Von Lueder TG, Krum H (2012) RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials. Cardiovasc Drugs Ther [Epub ahead of print].
4. Forbes JM, Cooper ME, (2013) Mechanisms of diabetic complications. Physiol Rev 93: 137-88.
5. Giacco F, Brownlee M, (2010) Oxidative stress and diabetic complications. Circ Res 107: 1058-70.
6. Akhtar S, Benter IF, (2013) The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. BioImpacts 3: 5-9.
7. Ciardiello F, Tortora G, (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.
8. Avraham R, Yarden Y, (2011) Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 12: 104-117.
9. Cai Z, Zhang H, Liu J, Berezov A, Murali R, et al. (2010) Targeting ErbB receptors. Semin Cell Dev Biol 21: 961-966.
10. Desai MD, Saroya BS, Lockhart AC, (2013) Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. Expert Opin Investig Drugs 22(3): 341-56.
11. Akhtar S, Yousif MH, Dhaunsi GS, Chandrasekhar B, Al-Farsi O, et al. (2012a) Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br J Pharmacol 165: 1390-400.
12. Almendro V, García-Recio S, Gascón P, (2010) Tyrosine kinase receptor transactivation associated to G protein-coupled receptors. Curr Drug Targets 11: 1169-1180.
13. Daub H, Weiss FU, Wallasch C, Ullrich A, (1996) Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379: 557-60.
14. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, et al. (2007) Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 112: 417-428.
15. Liebmann C, (2011) EGF receptor activation by GPCRs: a universal pathway reveals different versions. Mol Cell Endocrinol 331: 222-231.
16. Benter IF, Yousif MH, Griffiths SM, Benboubetra M, Akhtar S, (2005) Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. Br J Pharmacol 145: 829-836.
17. Benter IF, Yousif MH, Hollins AJ, Griffiths SM, Akhtar S, (2005) Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase. J Vasc Res 42: 284-291.
18. Benter IF, Benboubetra M, Hollins AJ, Yousif MH, Canatan H, et al. (2009) Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature. Vascul Pharmacol 51: 236-245.
19. Anand-Apte B, Ebrahem Q, Cutler A, Farage E, Sugimoto M, et al. (2010) Betacellulin induces increased retinal vascular permeability in mice. PLoS One 5: e13444.
20. Galán M, Kassan M, Choi SK, Partyka M, Trebak M, et al. (2012) A novel role for epidermal growth factor receptor tyrosine kinase and its downstream endoplasmic reticulum stress in cardiac damage and microvascular dysfunction in type 1 diabetes mellitus. Hypertension 60: 71-80.
21. Belmadani S, Palen DI, Gonzalez-Villalobos RA, Boulares HA, Matrougui K, (2008) Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 57: 1629-1637.
22. Dong M, Yan BP, Liao JK, Lam YY, Yip GW, et al. (2010) Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today 15: 622-9.
23. Zhou Q, Gensch C, Liao JK, (2011) Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 32: 167-73.
24. Surma M, Wei L, Shi J, (2011) Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol 7: 657-71.
25. Arita R, Hata Y, Nakao S, Kita T, Miura M, et al. (2009) Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 58: 215-26.
26. Schinzari F, Tesauro M, Rovella V, Di Daniele N, Gentileschi P, et al. (2012) Rho-kinase inhibition improves vasodilator responsiveness during hyperinsulinemia in the metabolic syndrome. Am J Physiol Endocrinol Metab 303: E806-11.
27. Zhao TT, Le Francois BG, Goss G, Ding K, Bradbury PA, et al. (2010) Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins. Oncogene 29: 4682-92.
28. Akhtar S, Yousif MH, Chandrasekhar B, Benter IF, (2012b) Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. PLoS One 7: e39066.
29. Yousif MH, Benter IF, Akhtar S, (2005) The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery. Auton Autacoid Pharmacol 25: 69-78.
30. Dhomen NS, Mariadason J, Tebbutt N, Scott AM, (2012) Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog 17: 31-50.
31. Suzuki K, Nemoto K, Ninomiya N, Kuno M, Kubota M, et al. (2012) Fasudil, a Rho-kinase inhibitor, attenuates lipopolysaccharide-induced vascular hyperpermeability and colonic muscle relaxation in guinea pigs. J Surg Res 178: 352-7.
32. Matsumoto T, Kakami M, Kobayashi T, Kamata K, (2008) Gender differences in vascular reactivity to endothelin-1 (1-31) in mesenteric arteries from diabetic mice. Peptides 29: 1338-46.
33. Mandavia CH, Aroor AR, Demarco VG, Sowers JR (2012) Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci [Epub ahead of print].
34. Maisch B, Alter P, Pankuweit S, (2011) Diabetic cardiomyopathy-fact or fiction? Herz 36: 102-15.
35. De Giusti VC, Nolly MB, Yeves AM, Caldiz CI, Villa-Abrille MC, et al. (2011) Aldosterone stimulates the cardiac Na(+)/H(+) exchanger via transactivation of the epidermal growth factor receptor. Hypertension 58: 912-9.
36. Kobayashi T, Eguchi S, (2012) The epidermal growth factor receptor: a missing link between endoplasmic reticulum stress and diabetic complications? Hypertension 60: 20-1.
37. Xu J, Wang G, Wang Y, Liu Q, Xu W, et al. (2009) Diabetes- and angiotensin II-induced cardiac endoplasmic reticulum stress and cell death: metallothionein protection. J Cell Mol Med 13: 1499-512.
38. Gao P, Wang XM, Qian DH, Qin ZX, Jin J, et al. (2012) Induction of Oxidative stress by Oxidized LDL via Meprinα-Activated Epidermal Growth Factor Receptor in Macrophages. Cardiovasc Res [Epub ahead of print].
39. Montezano AC, Touyz RM, (2012) Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann Med 44: S2-16.
40. Moon JY, Tanimoto M, Gohda T, Hagiwara S, Yamazaki T, et al. (2011) Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-Ay/Ta mice. Am J Physiol Renal Physiol [Epub ahead of print].
41. Wilkinson-Berka JL, Rana I, Armani R, Agrotis A, (2013) Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin Sci (Lond) 124: 597-615.
42. Li J, Zhu H, Shen E, Wan L, Arnold JM, et al. (2010) Deficiency of rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress, and reduces myocardial remodeling in a mouse model of type 1 diabetes. Diabetes 59: 2033-42.
43. Rodrigues-Díez R, Carvajal-González G, Sánchez-López E, Rodríguez-Vita J, Rodrigues Díez R, et al. (2008) Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res 25: 2447-61.
44. Shatanawi A, Romero MJ, Iddings JA, Chandra S, Umapathy NS, et al. (2011) Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am J Physiol Cell Physiol 300: C1181-92.
45. Liu B, Zhang JY, Cao HM, Wang Q, Wang HB, (2012) Effect of rosuvastatin on ROCK activity, endothelial function, and inflammation in Asian patients with atherosclerosis. Intern Med 51: 1177-82.
46. Hervent AS, De Keulenaer GW, (2012) Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics. Int J Mol Sci 13: 12268-86.
47. De Keulenaer GW, Doggen K, Lemmens K, (2010) The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 106: 35-46.
48. Schneider JW, Chang AY, Rocco TP, (2001) Cardiotoxicity in signal transduction therapeutics: ErbB2 antibodies and the heart. Semin Oncol 28: 18-26.
49. Izzo JL Jr, Zion AS, (2011) Value of Angiotensin receptor blocker therapy in diabetes. J Clin Hypertens (Greenwich) 13: 290-295.
50. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559.